Read Summary

In patients who had a D2 gastrectomy, perioperative administration of the oral fluoropyrimidine derivative S-1 and oxaliplatin yielded better outcomes than adjuvant capecitabine and oxaliplatin in a phase 3 trial.
Reuters Health Information

Print Friendly, PDF & Email